Roth Capital Upgrades Kodiak Sciences Inc. (KOD) to Buy

May 11, 2021 9:34 AM EDT
Get Alerts KOD Hot Sheet
Price: $99.89 -2.78%

Rating Summary:
    8 Buy, 5 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 15 | Down: 9 | New: 24
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Roth Capital analyst Zegbeth Jallah upgraded Kodiak Sciences Inc. (NASDAQ: KOD) from Neutral to Buy with a price target of $149.00.

The analyst comments "Yesterday, Kodiak press-released its 1Q2021 earnings and corporate updates. Most notable was the announcement that Kodiak will now be initiating an additional Phase 3 wAMD study to support 4-week interval dosing of its lead drug, KSI-301. We find the change necessary given Beovu's label challenges, and would not expect this to significantly shift the BLA timeline. With recent setbacks facing competitors, KSI-301's commercial outlook remains strong. Cash on hand is sufficient to execute on KSI-301, as well as KSI-501."

For an analyst ratings summary and ratings history on Kodiak Sciences Inc. click here. For more ratings news on Kodiak Sciences Inc. click here.

Shares of Kodiak Sciences Inc. closed at $88.41 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Upgrades

Related Entities

Roth Capital, Earnings